Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
IPO Year: 2022
Exchange: NASDAQ
Website: https://arcellx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $109.00 | Buy | Redburn Atlantic |
| 9/3/2024 | Overweight | Cantor Fitzgerald | |
| 5/31/2024 | $70.00 | Overweight | Piper Sandler |
| 3/7/2024 | $81.00 | Overweight | Morgan Stanley |
| 1/4/2024 | $65.00 → $71.00 | Buy | Needham |
| 12/19/2023 | $66.00 | Sector Outperform | Scotiabank |
| 10/30/2023 | Outperform | TD Cowen | |
| 10/17/2023 | $52.00 | Buy | UBS |
| 5/18/2023 | $60.00 | Buy | Truist |
| 4/14/2023 | $39.00 | Outperform | Robert W. Baird |
144 - Arcellx, Inc. (0001786205) (Subject)
10-Q - Arcellx, Inc. (0001786205) (Filer)
144 - Arcellx, Inc. (0001786205) (Subject)
8-K - Arcellx, Inc. (0001786205) (Filer)
8-K - Arcellx, Inc. (0001786205) (Filer)
144 - Arcellx, Inc. (0001786205) (Subject)
10-Q - Arcellx, Inc. (0001786205) (Filer)
8-K - Arcellx, Inc. (0001786205) (Filer)
144 - Arcellx, Inc. (0001786205) (Subject)
144 - Arcellx, Inc. (0001786205) (Subject)
-- Recently released ASH abstracts for the company's Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety profile -- -- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached -- -- Preliminary results from 58 patients enrolled in the Phase 2 pivotal iMMagine-1 study demonstrated 95% ORR and 62% CR/sCR at a median follow-up of 10.3 months; additional patients with a more recent data cut will be presented during an oral presentation -- -- No delayed neurotoxicities have been observ
-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached -- -- Preliminary results from 58 patients enrolled in the Phase 2 pivotal iMMagine-1 study demonstrated 95% ORR and 62% CR/sCR at a median follow-up of 10.3 months; additional patients with a more recent data cut will be presented during an oral presentation -- -- No delayed neurotoxicities have been observed to date with anito-cel, including no parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome across the Phase 1 and iMMagine-1 studies in the more than 140 patients dosed -- -- First patient dosed in iMMagine-3 s
-- Earned a $68M milestone payment from Kite for iMMagine-1 enrollment -- -- Submitted an abstract for the iMMagine-1 study at the 66th ASH Annual Meeting -- -- The global Phase 3 trial, iMMagine-3, has been initiated by Kite -- -- U.S. FDA clears anito-cel IND application for myasthenia gravis, an autoimmune disease -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2024. "We continue to make significant strides as we accelerate our business," said R
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite's Frederick, Maryland facility for iMMagine-3 as the successful technical transfer is complete -- -- Remain on track to present preliminary data from the iMMagine-1 trial by end of the year -- Kite, a Gilead Company (NASDAQ:GILD), and Arcellx, Inc. (NASDAQ:ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite's Frederick, Maryland facility for iMMagine-3 as the successful technical transfer is complete -- -- Remain on track to present preliminary data from the iMMagine-1 trial by end of the year -- Arcellx, Inc. (NASDAQ:ACLX) and Kite, a Gilead Company (NASDAQ:GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Cash, cash equivalents, and marketable securities: As of March 31, 2024, Arcellx had cash, cash equivalents, and marketable securities of $691.0 million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. Collaboration revenue: Collaboration revenue were $39.3 million and $17.9 million for the qu
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in two upcoming investor conferences: BofA Securities Health Care Conference 2024 (In Person) Presentation: Tuesday, May 14 at 3:40 p.m. PT TD Cowen 5th Annual Oncology Innovation Summit (Virtual) Fireside Chat: Tuesday, May 28 at 1:00 p.m. PT A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 30 days following the event.
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event. About Arcellx, Inc. Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative imm
Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event. About Arcellx, Inc. Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative
REDWOOD CITY, Calif., Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event. About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell t
Redburn Atlantic initiated coverage of Arcellx with a rating of Buy and set a new price target of $109.00
Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight
Piper Sandler initiated coverage of Arcellx with a rating of Overweight and set a new price target of $70.00
Morgan Stanley initiated coverage of Arcellx with a rating of Overweight and set a new price target of $81.00
Needham reiterated coverage of Arcellx with a rating of Buy and set a new price target of $71.00 from $65.00 previously
Scotiabank initiated coverage of Arcellx with a rating of Sector Outperform and set a new price target of $66.00
TD Cowen initiated coverage of Arcellx with a rating of Outperform
UBS initiated coverage of Arcellx with a rating of Buy and set a new price target of $52.00
Truist initiated coverage of Arcellx with a rating of Buy and set a new price target of $60.00
Robert W. Baird initiated coverage of Arcellx with a rating of Outperform and set a new price target of $39.00
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; $100M equity investment; and up to $3.9B in total contingent consideration -- -- Companies to co-commercialize and split profits in the U.S.; Arcellx to receive low to mid-teen royalties outside the U.S. -- -- Arcellx to continue independently progressing its development pipeline and researching new product candidates beyond myeloma -- -- Arcellx to host a conference call and webcast today at 5:45 a.m. PT -- REDWOOD CITY, Calif., and SANTA MONICA, Calif., Dec. 9, 2022 /PRNewswire/ -- Arcellx
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13D - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13D/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G/A - Arcellx, Inc. (0001786205) (Subject)
SC 13G - Arcellx, Inc. (0001786205) (Subject)
Arcellx (NASDAQ:ACLX) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 4 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $81.5, a high estimate of $87.00, and a low estimate of $70.00. A decline of 1.81% from the prior average price target
Canaccord Genuity analyst John Newman maintains Arcellx (NASDAQ:ACLX) with a Buy and maintains $85 price target.
Ratings for Arcellx (NASDAQ:ACLX) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 4 1 0 0 0 3M Ago 1 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.0, a high estimate of $87.00, and a low estimate of $70.00. This current average has decreased by 1.94% from the previous
Truist Securities analyst Asthika Goonewardene maintains Arcellx (NASDAQ:ACLX) with a Buy and maintains $87 price target.
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Arcellx (NASDAQ:ACLX) in the last three months. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 4 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 1 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.09, a high estimate of $87.00, and a low estimate of
Piper Sandler analyst Biren Amin initiates coverage on Arcellx (NASDAQ:ACLX) with a Overweight rating and announces Price Target of $70.
Stifel analyst Benjamin Burnett maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $82 to $83.
During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 10 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 3 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 5 3 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $80.57, a high estimate of $87.00, and a low estimate of $72.00. Witnessing a positive shift, the current average has rise
Evercore ISI Group analyst Cory Kasimov initiates coverage on Arcellx (NASDAQ:ACLX) with a Outperform rating and announces Price Target of $85.
HC Wainwright & Co. analyst Emily Bodnar maintains Arcellx (NASDAQ:ACLX) with a Buy and lowers the price target from $82 to $80.
REDWOOD CITY, Calif., June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Maryam Abdul-Kareem, J.D., as General Counsel. Ms. Abdul-Kareem brings extensive legal and business expertise in the biopharmaceutical industry, including serving in senior positions at Kinnate Biopharma and AstraZeneca. At Arcellx, she will oversee a broad spectrum of legal, contracts, and compliance matters.
FOSTER CITY, Calif., May 23, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Michelle Gilson as Chief Financial Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where most recently she served as Managing Director and Senior Equity Research Analyst covering biotechnology companies. Ms. Gilson will oversee the company's finance function and will play a key role in overall corporate strategy.
-- Replaces Lewis T. "Rusty" Williams, M.D., on Board of Directors -- FOSTER CITY, Calif., May 16, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Olivia Ware to its Board of Directors. Ms. Ware, a successful executive, brings a wealth of knowledge from her more than 20 years of experience in biotech and pharmaceutical drug development, commercialization, and healthcare management. "On
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)